

1 **Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-**  
2 **CoV-2 vaccines in naïve and previously infected individuals**

3 Duaa W. Al-Sadeq<sup>1,2†</sup>, Farah M. Shurrab<sup>1†</sup>, Ahmed Ismail<sup>3</sup>, Fathima Humaira Amanullah<sup>1</sup>,  
4 Swapna Thomas<sup>1,4</sup>, Nader Aldewik<sup>5</sup>, Hadi M. Yassine<sup>1,6</sup>, Hanan F. Abdul Rahim<sup>7</sup>, Laith Abu-  
5 Raddad<sup>8,9,10</sup>, Gheyath K. Nasrallah<sup>1,6\*</sup>

6 <sup>1</sup> Biomedical Research Center, Qatar University, Doha 2713, Qatar

7 <sup>2</sup> College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar

8 <sup>3</sup> Laboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar

9 <sup>4</sup> Department of Biological and Environmental Sciences, College of Arts and Science, Qatar  
10 University, P.O. Box 2713, Doha, Qatar

11 <sup>5</sup> Clinical and Metabolic Genetics Section, Pediatrics Department, Hamad General Hospital  
12 (HGH), Women's Wellness and Research Center (WWRC), Interim Translational Research  
13 Institute (iTRI), Hamad Medical Corporation (HMC), College of Health and Life Science  
14 (CHLS), Hamad Bin Khalifa University (HBKU), Doha, Qatar, P.O. Box 3050, Doha, Qatar

15 <sup>6</sup> Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University,  
16 P.O. Box 2713, Doha, Qatar

17 <sup>7</sup> College of Health Sciences, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar

18 <sup>8</sup> Infectious Disease Epidemiology Group, Weill Cornell Medicine–Qatar, Cornell University,  
19 Qatar Foundation – Education City, Doha, Qatar

20 <sup>9</sup> World Health Organization Collaborating Centre for Disease Epidemiology Analytics on  
21 HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar,  
22 Cornell University, Qatar Foundation – Education City, Doha, Qatar

23 <sup>10</sup> Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University,  
24 New York, United States of America

25 <sup>†</sup> Authors with equal contribution

26 **Correspondence to:** Gheyath K. Nasrallah, Department of Biomedical Science, College of  
27 Health Sciences, QU, Health, Qatar University, Doha 2713, Qatar. Tel: +974 4403 4817, Email:  
28 [gheyath.nasrallah@qu.edu.qa](mailto:gheyath.nasrallah@qu.edu.qa)

29

### 30 **Abstract**

31 Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, were granted the  
32 US Food and Drug Administration Emergency Use Authorization for preventing COVID-19.  
33 However, little is known about the difference in antibody responses induced by the two mRNA  
34 vaccines in naïve and individuals with a previous history of infections (PI group). Therefore, we  
35 investigated the levels of anti-S-RBD total antibodies (IgM, IgA, and IgG), anti-S-RBD IgG, and  
36 anti-S-RBD IgA in these two groups 1-13 (median=6) weeks following administration of two  
37 doses of mRNA-1273 or BNT162b2 vaccines. Results showed that in naïve-vaccinated group,  
38 the mRNA-1327 vaccine induces significantly higher levels of S-RBD total antibodies (3.5-fold;  
39  $p<0.001$ ), S-RBD IgG (2-fold- $p<0.01$ ), and S-IgA (2.1-fold,  $p<0.001$ ) than the BNT162b2  
40 vaccine. In the PI-vaccinated group, both vaccines produce significantly higher S-RBD total  
41 antibodies level than those of the naïve-vaccinated group. The PI group produced a higher level  
42 of S-RBD IgG than the naïve-BNT162b2 ( $p=0.05$ ) but not more than the naïve-mRNA-1273  
43 ( $p=0.9$ ) group. Interestingly, the PI-vaccinated group produced a comparable level of IgA ratio to  
44 the naïve-mRNA-1273 group but significantly higher than the naïve-BNT162b2 group (1.6-fold,  
45  $p<0.001$ ). Our results showed that the mRNA-1327 vaccine is more immunogenic and induces a  
46 greater antibody response than the BNT162b2 vaccine.

47

48 **Keywords:** Pfizer-BNT162b2, Moderna-mRNA-1273, S-RBD IgA, S-RBD IgG, Immune  
49 response

## 50 **1. Introduction**

51           Since the beginning of the COVID-19 pandemic, over 226 million people have been  
52 infected with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with more  
53 than four million deaths attributed to COVID-19 [1]. To combat the wide spread of SARS-CoV-  
54 2, major vaccination campaigns have been launched worldwide, with 3.9 billion vaccine doses  
55 provided to date [2]. In December 2020, the US Federal Food and Drug Administration (FDA)  
56 approved emergency authorization use (EAU) to Pfizer-BNT162b2 and Moderna-mRNA-  
57 1273COVID-19 vaccines.

58           Recent clinical studies and controlled trials have demonstrated the efficacy of the FDA-  
59 approved COVID-19 vaccines. The developed mRNA vaccines BNT162b2 (Pfizer-BioNTech)  
60 and mRNA-1273 (Moderna) were previously reported as safe vaccines with an efficacy rate of  
61 more than 94% [3, 4]. Recently we have demonstrated that the effectiveness of the mRNA-1273  
62 shows similar levels and patterns of protection to the BNT162b2 vaccine. Still, the mRNA-1273  
63 appears to be more robust against the SARS-CoV-2 B.1.351 variant and provides greater  
64 protection than the BNT162b2 [5]. However, the antibody immune response to different mRNA  
65 COVID-19 vaccines has not been extensively studied, emphasizing the need to evaluate the  
66 FDA-authorized vaccines' durability and comparative efficacy. Therefore, this study aims to  
67 compare the antibody immune responses between the mRNA-1273 and BNT162b2 SARS-CoV-  
68 2 vaccines after administering two doses in naïve and previously infected participants. Qatar is  
69 currently administering the BNT162b2 and mRNA-1273 vaccines. Both vaccines have been  
70 approved for emergency use by the Department of Pharmacy and Pharmaceutical Control in the  
71 Ministry of Public Health.

72

## 73 **2. Material and Methods**

### 74 **2.1 Ethical approval and sample collection**

75 Randomized participants who received two doses of either BNT162b2 or mRNA-1273  
76 vaccine were eligible for inclusion. A total of 289 samples were collected from staff and students  
77 of Qatar University, the national university Qatar, with different age groups and nationalities.  
78 Peripheral blood was collected 1-13 (BNT162b2 median=6, mRNA-1273 median=5, PI  
79 median=6) weeks following the administration of the second dose of vaccine. Participants were  
80 either naïve or previously infected (PI) with SARS-CoV-2. The study was reviewed and  
81 approved by the Institutional Review Board at Qatar University (QU-IRB 1537-FBA/21). Plasma  
82 was separated from venous whole blood collection and stored at -80 °C until performing the  
83 immunoassays testing. Demographic information was collected through a self-administered  
84 questionnaire. In addition, the questionnaire included questions regarding the previous history of  
85 infection.

### 86 **2.2 Serology testing**

87 Serological testing was done using the automated analyzer CL-900i® from Mindray Bio-  
88 Medical Electronics [6-8] using two chemiluminescence immunoassays to detect the vaccine-  
89 induced antibodies: (i) The SARS-CoV-2 S-RBD IgG (catalog No. SARS-CoV-2 S-RBD  
90 IgG122, Mindray, China), the cut off index for the kit is  $\geq 10-1000$  BAU/mL, and (ii) The anti-S-  
91 RBD SARS-CoV-2 total antibodies (IgG, IgA, and IgM) (Catalog No. SARS-CoV-2 Total  
92 Antibodies 122, Mindray, China) with positive cut off index of  $\geq 10-2000$  AU/mL. All samples  
93 with readings higher than the reference range were diluted with phosphate-buffered saline (PBS).  
94 In addition, the Euroimmun anti-SARS-CoV-2 IgA ELISA (Catalog No. EI 2606-9601 A,  
95 Germany) was used to measure the anti-S1 antibody levels [9]. The IgA ratio was calculated by

96 dividing the extinction of the sample by the calibrator. Ratios  $\geq 1.1$  are considered positive,  $<0.8$   
97 are negative, and  $\geq 0.8$  to  $<1$  are borderline. Some samples were not tested for IgA (40/289)  
98 because of limited plasma volume. All tests were carried out according to the manufacturers'  
99 instructions.

100 In addition to the information collected by the questionnaire about the previous history of  
101 infection, we used nucleoprotein-specific IgG (anti-N IgG) to denote prior SARS-CoV-2  
102 exposure. That is, the naïve, but not the previously infected volunteers, do not produce IgG to the  
103 N protein. Thus, the previous infection is defined as anti-N positivity and/or reported history of  
104 positive polymerase chain reaction results on the nasopharyngeal swab. All samples were tested  
105 for the presence of anti-N SARS-CoV-2 IgG using the Architect automated chemiluminescent  
106 assay (Abbott Laboratories, USA) according to the manufacturers' instructions [8].

### 107 **2.3 Statistical analysis**

108 Data were analyzed using GraphPad Prism 9.2.0. (San Diego, CA, USA). Results in the  
109 graphs are plotted as mean values with standard deviation (SD). One-way ANOVA tests were  
110 performed to compare the groups, and p values  $<0.05$  were considered statistically significant. In  
111 all graphs, \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , and \*\*\* $p \leq 0.001$ .

112

## 113 **3. Results**

### 114 **3.1 Participant characteristic**

115 Participants' characteristics are described in Table 1. A total of 289 mRNA naïve  
116 vaccinated and PI vaccinated volunteers participated in this study. Of those, 218 were  
117 BNT162b2 naïve vaccinated, 45 naïve mRNA-1273 vaccinated, and 26 PI vaccinated

118 participants (23 with BNT162b2 vaccine and 3 with mRNA-1273 and). Further details about  
119 participants are provided in Table S1 and S2.

## 120 **3.2 Antibody immune response assessment following vaccination**

### 121 **3.2.1 S-RBD total antibodies response**

122 All naïve-BNT162b2, naïve-mRNA-1273, and PI vaccinated group has positive total  
123 antibodies response (Figure 1A), with mean levels of  $4.6 \times 10^3$  AU/mL (95%CI:  $3.0-6.2 \times 10^3$ ),  
124  $1.6 \times 10^4$  AU/mL (95%CI:  $6.1 \times 10^3-2.7 \times 10^4$ ), and  $3.0 \times 10^4$  AU/mL (95%CI:  $1.4-4.6 \times 10^4$ ),  
125 respectively. The naïve-mRNA-1273 vaccinated group produced significantly higher total  
126 antibodies level than the naïve-BNT162b2 (4-fold,  $p < 0.01$ ). The PI vaccinated group produced  
127 significantly higher levels of total S-RBD total antibodies compared to the naïve-BNT162b2  
128 (6.5-fold;  $p < 0.001$ ) and naïve-mRNA-1273 (1.9 fold,  $p < 0.05$ ) vaccinated group.

### 129 **3.2.2 S-RBD IgG response**

130 S-RBD IgG response was detected in all naïve-BNT162b2, naïve-mRNA-1273, and PI  
131 vaccinated groups (Figure 1B). The mean IgG levels were  $2.3 \times 10^3$  BAU/mL (95%CI:  $1.8-$   
132  $2.8 \times 10^3$ ),  $4.6 \times 10^3$  BAU/mL (95%CI:  $3.4-5.7 \times 10^3$ ),  $4.3 \times 10^3$  BAU/mL (95%CI:  $2.6-5.9 \times 10^3$ ),  
133 respectively. The naïve-mRNA-1273 group produced significantly higher IgG levels compared  
134 to the naïve-BNT162b2 vaccinated group (2-fold,  $p = 0.002$ ). Interestingly, The PI group  
135 produced a higher level of S-RBD IgG than the naïve-BNT162b2 ( $p = 0.05$ ) but not more than the  
136 naïve-mRNA-1273 ( $p = 0.9$ ) vaccinated group.

### 137 **3.2.3 S-RBD IgA response**

138 IgA antibodies were detected in all naïve-mRNA-1273 and PI vaccinated groups (Figure  
139 1C). However, in the naïve-BNT162b2 group, 96.8% (184/190) were positive to anti-S IgA,  
140 1.6% (3/190) were negative, and 1.6% (3/190) were borderline. The mean IgA ratios were 7.9

141 (95%CI: 7.1-8.7) in the naïve-BNT162b2, 16.4 (95%CI: 13.5-19.2) in the naïve-mRNA-1273,  
142 and 14.1 (95%CI: 10.1-18.1) in the PI vaccinated group. No significant difference in the IgA  
143 level was detected between the PI and naïve-mRNA-1273 vaccinated group ( $p=0.4139$ ).  
144 However, the naïve-BNT162b2 vaccinated group produced a significantly lower IgA ratio than  
145 was observed in naïve-mRNA-1273 and the PI vaccinated group ( $P<0.001$ ). Collectively, our  
146 results indicate that the mRNA-1273 vaccine induces a significantly higher IgA antibody  
147 response in the naïve and the PI vaccinated individuals compared to the BNT162b2 vaccine.

### 148 **3.3 Age effect on antibody response**

149 Samples from the naïve-BNT162b2 vaccinated participants were categorized in different  
150 age groups <30, 30-50, and >50 years old; the mean total antibodies level for each group was  
151  $3.7 \times 10^3$  AU/mL,  $4.7 \times 10^3$  AU/mL, and  $6.7 \times 10^3$  AU/mL, respectively. The mean S-RBD IgG  
152 level for each group was  $2.8 \times 10^3$  BAU/mL,  $2.2 \times 10^3$  BAU/mL, and  $1.5 \times 10^3$  BAU/mL,  
153 respectively. The mean anti-S IgA levels for each group were 9.5, 7.2, and 6.4, respectively.  
154 Although there are differences in all antibody responses between the three age groups, however,  
155 this difference was not significant ( $P>0.05$ ) (Figure 2).

## 156 **4. Discussion**

157 The mRNA vaccines BNT162b2 and mRNA-1273 offer great promise for curbing the  
158 spread of SARS-CoV-2 infection. They showed an efficacy rate of more than 94% [3, 4] and  
159 were reported to be safe. Recently we have demonstrated that the effectiveness of the mRNA-  
160 1273 shows similar levels and patterns of protection to the BNT162b2 vaccine [10]. However,  
161 the mRNA-1273 appears to be more robust against B.1.351 and provides greater protection than  
162 the BNT162b2 [5]. A relationship between neutralization level after SARS-CoV-2 vaccination  
163 and protection against COVID-19 was previously emphasized [11]. The level of the antibody

164 response after vaccination correlates with neutralizing antibody titers, which might be clinically  
165 significant [12]. In the current study, robust antibody response was clearly observed in both  
166 mRNA vaccinated participants. All participants elicited anti-S-RBD total antibodies and anti-S-  
167 RBD IgG and almost all produced S-RBD-IgA (Figure 1). Yet, differences were observed in  
168 antibody response between BNT162b2 and mRNA-1273 groups. To our knowledge, there is only  
169 one published report with similar vaccinated group criteria that showed parallel results to ours  
170 [13]. The novelty of our study stems from testing three different parameters to measure antibody  
171 response in mRNA vaccine participants, including the IgA response, which was not previously  
172 measured [13]. Natural infection mediates viral neutralization through the production of IgA  
173 antibodies. However, little is known regarding the vaccine-induced immune response [14].  
174 Interestingly, a recent study demonstrated that IgA dominates the early neutralizing antibody  
175 response to SARS-CoV-2 [15] and this could be clinically significant for protection. We  
176 specifically tested the total and the IgG response not to the whole spike S protein but only to the  
177 spike protein S-receptor-binding domain (S-RBD). We expect the anti-SRBD antibodies to  
178 specifically correlate with the antibody neutralizing activity as both targeted the S-RBD.

179 Wheeler et al. [16] reported no differences in antibody responses (anti-S1, anti-RBD, and  
180 anti-S2) between mRNA-1273 and BNT162b after receiving the first or the second dose. Here  
181 we showed that the mRNA-1273 vaccine significantly produces higher antibody response levels  
182 for S-RBD IgG, anti-S IgA, and total antibodies compared to BNT162b2 with at least two-fold in  
183 all antibody tested parameters (Figure 1). Our study results are in agreement with several other  
184 reports [13]. For instance, a recent study demonstrated that the mRNA-1273 vaccine produces a  
185 significantly higher total antibodies level to the whole S-spike protein with the BNT162b2  
186 vaccine in both infected and uninfected groups. Besides, this was observed across different age

187 categories (14). The differences in the level of antibody response are potentially due to each  
188 vaccine's formulation, dose content, and the interval between the doses. It was reported that  
189 mRNA-1273 has higher mRNA content than BNT162b2 (100 $\mu$ g vs. 30 $\mu$ g, respectively). Another  
190 factor could be the time elapsed between the first and second doses [5]. For instance, the mRNA-  
191 1273 vaccine has two doses 28 days apart, while BNT162b2 is 21 days apart. Therefore, this  
192 might have affected the build-up of immunity after vaccination.

193 As expected, we showed that PI participants who received two doses of mRNA vaccines  
194 produced significantly higher total antibodies titers compared to the naïve vaccinated group  
195 (Figure 1A), which is in agreement with a previous study [13]. In addition, PI vaccinated  
196 produced higher antibody levels compared to the naïve BNT162b2 vaccinated group. However,  
197 no significant difference in the levels of S-RBD IgG and anti-S IgA was observed between PI  
198 vaccinated, and naïve mRNA-1273 vaccinated individuals (Figure 1B). These results emphasize  
199 that the elicited antibodies in response to mRNA vaccines include IgA and IgM, which explains  
200 the differences in the total antibodies level (Figure 1A). In addition, our PI cohort included  
201 samples with different times of infection, which might explain the variation in antibody titers and  
202 response to the vaccine. The reason why mRNA-1273 produced higher IgA levels needs further  
203 investigation, whether this could be due to dose-effect or the duration between the two doses.

204 On the other hand, it was expected that there is a distinct SARS-CoV-2 viral-specific  
205 antibody response and varies based on age. Although we showed that the <30 group produces  
206 higher levels than the other two groups, however, this difference was not significant ( $P>0.5$ )  
207 (Figure 2). Some studies reported that the initial response to different SARS-CoV-2 antigens is  
208 age-dependent. For instance, Jalkanen et al. reported that after receiving the first dose of  
209 BNT162b2, the levels of antibodies were significantly lower in the old age group (>50)

210 compared to the younger age groups. However, The difference in antibody responses disappears  
211 after receiving the second dose [17]. In fact, Wheeler et al. [16] reported the minimal effect of  
212 age and gender on antibody responses after vaccination.

213 In conclusion, our ongoing study showed that the antibody response induced by mRNA-  
214 1327 was approximately three-fold higher than BNT162b2. In addition, higher total antibodies  
215 titer was reported in PI vaccinated compared to naïve vaccinated participants. While both mRNA  
216 SARS-CoV-2 vaccines have high efficacy and strongly protect against infection, mRNA-1327  
217 remains the most effective over time. The study has some limitations; other immune parameters  
218 (SRBD-IgM and the neutralizing antibodies), the durability, and the kinetics of antibodies after  
219 vaccination need further investigation to provide a complete immune response profile. Further,  
220 most of the PI group received the BNT162b2 and only few received the mRNA-1327 vaccine.

221

222 **Funding**

223 This work was made possible by grant number UREP28-173-3-07 from the Qatar National  
224 Research Fund (a member of Qatar Foundation). The statements made herein are solely the  
225 responsibility of the authors.

226 **Conflict of interest**

227 The authors would like to declare that there is no conflict of interest.

228 **Acknowledgment**

229 We would like to thank Ms. Sahar Aboalmaaly, Ms. Afra Al Farsi, Ms. Reeham Al-Buainain,  
230 Ms. Samar Ataelmannan, and Ms. Jiji Paul, the laboratory technologists at the Medical  
231 Commission Laboratory Section, Ministry of Public Health, Qatar, for their help in  
232 performing the Architect® immunoassay.

233

**Table 1.** Demographic characteristics of the study sample ( $n = 289$ ).

Characteristic		BNT162b2 (%)		mRNA-1273 (%)	
		Naïve	PI	Naïve	PI
Gender	Male	114 (52.29)	14 (60.86)	23 (51.11)	1 (33.33)
	Female	104 (47.70)	9 (39.13)	22 (48.88)	2 (66.66)
	Total	218	23	45	3
Age (years)	<30	71 (43.29)	8 (34.78)	26 (57.77)	1 (33.33)
	30–50	104 (50.24)	14 (60.86)	16 (35.55)	2 (66.66)
	>50	32 (15.45)	1 (4.34)	2 (4.44)	-
	Unknown	-	-	1 (2.22)	-
	Total	218	23	45	3

234

235

236 **Figure Legend**

237 **Figure 1.** Antibody levels in mRNA vaccinated participants after 1-13 (median=6) weeks of  
238 receiving two doses, and participants with prior infection with two doses of vaccine. The tests  
239 were performed using the automated analyzer Mindray CI-900i (A) S-RBD Total antibodies  
240 level (AU/mL) (B) S-RBD IgG antibody levels (BAU/mL) (C) anti-S IgA antibody levels using  
241 Euroimmun ELISA. ns  $p > 0.05$ , \*  $p \leq 0.05$ , \*\*  $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ .

242

243 **Figure 2** Antibody levels in BNT162b2 vaccinated participants according to age groups. (A)  
244 Total antibodies level (Au/ml) (B) S-RBD IgG antibody levels (BAU/ml). (C) anti-S IgA  
245 antibody levels. ns  $P > 0.05$ .

246

247

248

249 **References**

- 250 1. Center, J.H.C.R., *COVID-19 Map*. 2021.
- 251 2. Ritchie, H., et al., *Coronavirus pandemic (COVID-19)*. Our World in Data, 2020.
- 252 3. Baden, L.R., et al., *Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine*. New  
253 England Journal of Medicine, 2020. **384**(5): p. 403-416.
- 254 4. Polack, F.P., et al., *Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine*. New  
255 England Journal of Medicine, 2020.
- 256 5. Chemaitelly, H., et al., *mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7  
257 and B. 1.351 variants and severe COVID-19 disease in Qatar*. Nature medicine, 2021: p.  
258 1-8.
- 259 6. Nasrallah, G.K., et al., *Analytic comparison between three high-throughput commercial  
260 SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence  
261 population*. Scientific reports, 2021. **11**(1): p. 1-10.
- 262 7. Younes, S., et al., *Diagnostic efficiency of three fully automated serology assays and  
263 their correlation with a novel surrogate virus neutralization test in symptomatic and  
264 asymptomatic SARS-COV-2 individuals*. Microorganisms, 2021. **9**(2): p. 245.
- 265 8. Ismail, A., et al., *Can commercial automated immunoassays be utilized to predict  
266 neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three  
267 different assays*. 2021.
- 268 9. Gededzha, M.P., et al., *Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA  
269 Assay for detection of IgA and IgG antibodies in South Africa*. PloS one, 2021. **16**(6): p.  
270 e0252317.
- 271 10. Abu-Raddad, L.J., H. Chemaitelly, and A.A. Butt, *Effectiveness of the BNT162b2 Covid-  
272 19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants*. New England Journal of  
273 Medicine, 2021.
- 274 11. Khoury, D., D. Cromer, and A. Reylandi, *Neutralizing antibody levels are highly  
275 predictive of immune protection from symptomatic SARS-CoV-2 infection [published  
276 online ahead of print May 17, 2021]*. Nat Med. doi. **10**.
- 277 12. Rubio-Acero, R., et al., *In Search of the SARS-CoV-2 Protection Correlate: Head-to-  
278 Head Comparison of Two Quantitative SI Assays in Pre-characterized Oligo-  
279 /Asymptomatic Patients*. Infectious diseases and therapy, 2021: p. 1-14.
- 280 13. Steensels, D., et al., *Comparison of SARS-CoV-2 antibody response following  
281 vaccination with BNT162b2 and mRNA-1273*. JAMA, 2021.

- 282 14. Wisnewski, A.V., J. Campillo Luna, and C.A. Redlich, *Human IgG and IgA responses to*  
283 *COVID-19 mRNA vaccines*. Plos one, 2021. **16**(6): p. e0249499.
- 284 15. Sterlin, D., et al., *IgA dominates the early neutralizing antibody response to SARS-CoV-2*.  
285 *Science translational medicine*, 2021. **13**(577).
- 286 16. Wheeler, S.E., et al., *Differential Antibody Response to mRNA COVID-19 Vaccines in*  
287 *Healthy Subjects*. Microbiology Spectrum, 2021. **9**(1): p. e00341-21.
- 288 17. Jalkanen, P., et al., *COVID-19 mRNA vaccine induced antibody responses against three*  
289 *SARS-CoV-2 variants*. Nature Communications, 2021. **12**(1): p. 3991.
- 290











